Prescribing information

 

Prescribing information

       

Welcome to the ILARIS: On-demand webinars page. Below you can access the latest educational webinars organised by Novartis and hosted by experts in their field.

Contact your Novartis representative if you would like to express interest in registering for future events.

Contact us

 

FMF: Optimising Patient Care

 

Click here for ILARIS® (canakinumab) prescribing information.

 

Speakers: Prof. Dr. Jasmin Kümmerle-Deschner, Division of Paediatric Rheumatology, Department of Paediatrics and Autoinflammation Reference Centre, University Hospital Tübingen, Germany.
Prof. Dr. Maria Cristina Maggio, Dipartimento PROMISE G. D’Alessandro Università degli Studi di Palermo, Ospedale dei Bambini, ARNAS, Palemo. 

The Paediatric Rheumatology Congress (PReS) webinar is in two parts. Firstly, paediatric rheumatologist Prof. Dr. Jasmin Kümmerle-Deschner discusses a case study of a young patient with FMF, his treatment goals and targeting disease control through IL-1 inhibition. Secondly, paediatric rheumatologist Prof. Dr. Maria Cristina Maggio explores the key principles in the management of patients with FMF, with a specific focus on improving QoL and patient engagement.

Indication:
ILARIS is indicated for the treatment of the following autoinflammatory periodic fever syndromes in adults, adolescents and children aged 2 years and older:1

  • Cryopyrin-associated periodic syndromes (CAPS), including: 
    • Muckle-Wells syndrome (MWS)
    • Neonatal-onset multisystem inflammatory disease (NOMID)/chronic infantile neurological, cutaneous, articular syndrome (CINCA)
    • Severe forms of familial cold autoinflammatory syndrome (FCAS)/familial cold urticaria (FCU) presenting with signs and symptoms beyond cold-induced urticarial skin rash.
  • Tumour necrosis factor (TNF) receptor-associated periodic syndrome (TRAPS).
  • Hyperimmunoglobulin D syndrome (HIDS)/mevalonate kinase deficiency (MKD).
  • Familial Mediterranean fever (FMF). ILARIS should be given in combination with colchicine, if appropriate.

 

FMF, familial Mediterranean fever;  IL, interleukin; QoL, quality of life.

Reference   

  1. ILARIS® (canakinumab) Summary of Product Characteristics.
Rate this content: 
No votes yet
UK | March 2022 | 174743
×

Ask Speakers

×

Medical Information Request

Adverse events should be reported. Reporting forms and information can be found at www.mhra.gov.uk/yellowcard. Adverse events should also be reported to Novartis via [email protected] or online through the pharmacovigilance intake (PVI) tool at www.report.novartis.com
If you have a question about the product, please contact Medical Information on 01276 698370 or by email at [email protected]